Grifols, S.A. vs Perrigo Company plc: SG&A Expense Trends

SG&A Expense Trends: Grifols, S.A. vs Perrigo Company plc

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Grifols, S.A. and Perrigo Company plc from 2014 to 2023. Over this period, Grifols, S.A. has seen a steady increase in SG&A expenses, growing by approximately 90%, reflecting its strategic investments in global expansion and innovation. Meanwhile, Perrigo Company plc's SG&A expenses have also risen, albeit at a slower pace of around 89%, indicating a focus on maintaining operational efficiency while expanding its product portfolio. Notably, both companies experienced significant expense spikes in 2022, with Grifols reaching 1.19 billion and Perrigo at 1.21 billion, highlighting the competitive landscape and the need for strategic spending. This financial insight provides a window into the operational strategies of these pharmaceutical giants.